Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials

Stem Cell Research & Therapy, Год журнала: 2025, Номер 16(1)

Опубликована: Янв. 6, 2025

Chronic liver diseases, including cirrhosis and failure, remain formidable challenges due to their complex progression limited therapeutic options. Mesenchymal stem cell (MSC) therapy has emerged as a game-changing approach, leveraging its potent immunomodulatory, anti-fibrotic, regenerative capabilities, along with the ability transdifferentiate into hepatocytes. This review delves latest advances in MSC-based treatments for chronic end-stage highlighted current clinical trials. MSCs derived from bone marrow umbilical cord have shown remarkable promise reversing damage, improving function, providing hope patients who do not respond conventional therapies. When administered through hepatic, portal, or peripheral veins, significantly improved histology, reduced fibrosis, restored functional capacity. Furthermore, MSC-derived materials, such extracellular vesicles exosomes, are emerging cutting-edge tools treating failure mitigating post-transplant complications. While autologous hepatocytes hold non-fatal cirrhosis, allogeneic being applied more severe conditions, transplantation cases. Despite these promising early outcomes, larger trials long-term studies essential fully harness transformative, off-the-shelf alternative transplantation, heralding new era

Язык: Английский

---

Smart Microneedle Arrays Integrating Cell‐Free Therapy and Nanocatalysis to Treat Liver Fibrosis

Advanced Science, Год журнала: 2024, Номер 11(31)

Опубликована: Июнь 14, 2024

Abstract Liver fibrosis is a chronic pathological condition lacking specific clinical treatments. Stem cells, with notable potential in regenerative medicine, offer promise treating liver fibrosis. However, stem cell therapy hindered by immunological rejection, carcinogenesis risk, efficacy variation, and high cost. secretome‐based cell‐free offers solutions to address these challenges, but it limited low delivery efficiency rapid clearance. Herein, an innovative approach for situ implantation of smart microneedle (MN) arrays enabling precisely controlled multiple therapeutic agents directly into fibrotic tissues developed. By integrating platinum‐based nanocatalytic combination therapy, the MN can deactivate hepatic stellate cells. Moreover, they promote excessive extracellular matrix degradation more than 75%, approaching normal levels. Additionally, provide hepatocyte protection while reducing inflammation levels ≈70–90%. They also exhibit remarkable capability scavenging almost 100% reactive oxygen species alleviating hypoxia. Ultimately, this treatment strategy effectively restrain progression. The comprehensive vitro vivo experiments, supplemented proteome transcriptome analyses, substantiate effectiveness fibrosis, holding immense applications.

Язык: Английский

---

Fucoxanthin Enhances the Antifibrotic Potential of Placenta-derived Mesenchymal Stem Cells in a CCl4-induced Mouse Model of Liver

Current Stem Cell Research & Therapy, Год журнала: 2024, Номер 19(11), С. 1484 - 1496

Опубликована: Янв. 11, 2024

The effectiveness of fucoxanthin (Fx) in liver diseases has been reported due to its anti-inflammatory and antifibrotic effects. Mesenchymal stem cells (MSCs)-based therapy also proposed as a promising strategy for fibrosis treatment. Recent studies have shown that the co-administration MSCs drugs demonstrates pronounced effect on fibrosis.

Язык: Английский

---

Mesenchymal stem cell and exosome-based therapy for liver diseases: can it overcome conventional therapeutic inconsistencies?

Опубликована: Янв. 15, 2025

Liver inflammation, injury, and hepatic cell death are caused by external agents (viruses, bacteria, drugs, alcohol, etc.) along with the genetic susceptibility of an individual. Persistent activation fibrogenic response in cells leads to liver fibrosis which turn progresses cirrhosis cancer. The dysregulation immune system generates reactive oxygen species induce necrosis hepatocytes. This process activates stellate myofibroblasts produce a huge quantity collagens, alpha-smooth muscle actin, extracellular matrix deposition parenchyma. Due multifactorial nature this disease, conventional therapies increasingly attempted combinatorial therapy or polytherapy target multiple mechanistic sites order prevent entry into further complicated irreversible stages. Despite advancements therapy, several cases aggravate (grade 3 4) cirrhosis. inconsistency treatment outcomes limited organ donors for transplantation have led ever-increasing challenging demand alternative therapies. In review, we analyze mechanism causative factors diseases, mode, therapeutic options. central diseases dysregulation, hence bioactive immunomodulatory properties should be searched exploited meet needs. Mesenchymal stem (MSCs) their specialized anti-inflammatory could utilized as effective candidate treating inflammatory diseases. MSC-derived exosome provides additional option that work tandem MSC synergistic form. series, reviewed preconditioned genetically edited MSCs augment homing, proliferation, differentiation. Importantly, all clinical challenges noted addressed before cytotherapy considered safe patients Published literature indicated has potential substitute options high-grade

Язык: Английский

---

Extracellular vesicles from mesenchymal stem cells improve liver injury in rats with mild liver damage. Underlying mechanisms and role of TGFβ

Life Sciences, Год журнала: 2025, Номер 364, С. 123429 - 123429

Опубликована: Янв. 28, 2025

Язык: Английский

---

Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials

Stem Cell Research & Therapy, Год журнала: 2025, Номер 16(1)

Опубликована: Март 7, 2025

Язык: Английский

---

Experience of using mononuclear stem cells in combination with endovascular methods for the correction of portal hypertension in liver cirrhosis patients

Annaly khirurgicheskoy gepatologii = Annals of HPB surgery, Год журнала: 2025, Номер 30(1), С. 11 - 19

Опубликована: Фев. 28, 2025

Aim . To justify the necessity of combined intraportal administration mononuclear stem cells, transjugular intrahepatic portosystemic shunting, and partial splenic embolization in patients with portal hypertension hepatocellular insufficiency against background liver cirrhosis, to develop a technology, evaluate its safety efficacy. Materials methods The study involved results treatment for 1631 cirrhosis various etiologies from 2018 2023; 272 (16.7%) were included waiting list cadaveric transplantation. During period, 195 (71.6%) underwent some method surgical correction hypertension: 84 (43.1%) endoscopic ligation esophageal varices, 46 (23.6%) had 21 (10.7%) received embolization, 35 (17.9%) both shunting one procedure. In 15 cases (5.5%), autologous bone marrow cells was performed. 9 (4.7%), this technology minimally invasive correcting 6 (3.1%) 3 (1.6%) embolization. Results Following techniques complications hypertension, no or adverse events observed. average follow-up period (3;15) months, MELD score during dynamic observation 16 (12;18) points. No progression related noted. Conclusion combination represents promising, effective, safe strategy reducing mortality awaiting transplantation improving outcomes terminal diffuse diseases.

Язык: Английский

---

The Therapeutic Use and Potential of MSCs: Advances in Regenerative Medicine

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3084 - 3084

Опубликована: Март 27, 2025

Mesenchymal stem cells (MSCs) have emerged as a relevant strategy in regenerative medicine due to their multipotent differentiation capacity, immunomodulatory properties, and therapeutic applications various medical fields. This review explores the use of MSCs, focusing on role treating autoimmune disorders neoplastic diseases tissue regeneration. We discuss mechanisms underlying MSC-mediated repair, including paracrine activity, migration injury sites, interaction with immune system. Advances cellular therapies such genome engineering MSC-derived exosome treatments further enhance applicability. Key methodologies analyzed include genomic studies, next-generation sequencing (NGS), bioinformatics approaches optimize MSC-based interventions. Additionally, we reviewed preclinical clinical evidence demonstrating potential MSCs conditions graft-versus-host disease, osteoarthritis, liver cirrhosis, neurodegenerative disorders. While promising, challenges remain regarding standardization, long-term safety, tumorigenic risks associated MSC therapy. Future research should focus refining efficacy minimize risks. underscores need for large-scale trials validate interventions fully harness potential.

Язык: Английский

---

New insights on mesenchymal stem cells therapy from the perspective of the pathogenesis of nonalcoholic fatty liver disease

Digestive and Liver Disease, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

---

The efficacy of different doses of citicoline in improving the prognosis of patients with acute ischemic stroke based on network meta-analysis

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 4, 2025

Objective Our group aimed to explore the effect of different dosages citicoline on ischemic stroke (IS) patients and determine most appropriate dosage for these patients. Methods The databases PubMed, Cochrane Library, Medline, Web Science, Embase were searched from their establishment 15 October 2024. We assessed quality all included articles by using evaluation method or Newcastle-Ottawa Scale (NOS), which was based study type. Relative risk (RR) 95% confidence interval (CI) used dichotomous data, mean standardized difference (SD) continuous data. outcome indicators death, improvement in neurological function daily living activities, adverse effects. Results In this study, a total 13 studies included. Of these, 370 treated with 500 mg citicoline, 502 1,000 1,891 2,000 2,582 control (CON). evaluated treatment ranking. terms both demonstrated lower mortality than CON, having lowest mortality. improvement, we found that compared rates higher ineffective results 500-mg 2,000-mg 1,000-mg groups. MBI scores 2000 while score not. Lastly, aspect effects, rate effects it citicoline. Conclusion research findings revealed significantly affect function, acute IS. Notably, not only demonstrate activities but also have results. However, does specify best one two dosages.

Язык: Английский

---